Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors

PeerVoice
30 de May de 2023••
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors
1 de 34

Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors

30 de May de 2023••
Descargar para leer sin conexión
Salud y medicina

James F. Howard Jr, MD, Ali A. Habib, MD, and Nicholas J. Silvestri, MD, discuss myasthenia gravis in this IME activity titled "Complement-Mediated Attack of the Neuromuscular Junction in gMG: The C5 Inhibitors." For the full presentation, please visit us at www.peervoice.com/QQG870.

PeerVoice

Recomendados

Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and TargetingCatching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and TargetingPeerVoice4 vistas•28 diapositivas
Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now...Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now...
Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now...PeerVoice9 vistas•72 diapositivas
Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL:...Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL:...
Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL:...PeerVoice4 vistas•30 diapositivas
Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and ...Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and ...
Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and ...PeerVoice27 vistas•40 diapositivas
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...
Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted ...PeerVoice5 vistas•29 diapositivas
Designing Treatment Regimens to Suppress Multidrug-Resistant HIV: What Would ...Designing Treatment Regimens to Suppress Multidrug-Resistant HIV: What Would ...
Designing Treatment Regimens to Suppress Multidrug-Resistant HIV: What Would ...PeerVoice5 vistas•20 diapositivas

Más contenido relacionado

Más de PeerVoice

Achieving Shared Goals Across the Spectrum of CKD and HFAchieving Shared Goals Across the Spectrum of CKD and HF
Achieving Shared Goals Across the Spectrum of CKD and HFPeerVoice32 vistas•32 diapositivas
Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Establis...Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Establis...
Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Establis...PeerVoice4 vistas•27 diapositivas
Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Ex...Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Ex...
Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Ex...PeerVoice10 vistas•85 diapositivas
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...PeerVoice6 vistas•29 diapositivas
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...PeerVoice6 vistas•3 diapositivas
Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical ConsiderationsOncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical ConsiderationsPeerVoice5 vistas•28 diapositivas

Más de PeerVoice(20)

Achieving Shared Goals Across the Spectrum of CKD and HFAchieving Shared Goals Across the Spectrum of CKD and HF
Achieving Shared Goals Across the Spectrum of CKD and HF
PeerVoice•32 vistas
Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Establis...Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Establis...
Managing the Cost of Type 2 Diabetes: The Impact of Effective Use of Establis...
PeerVoice•4 vistas
Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Ex...Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Ex...
Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Ex...
PeerVoice•10 vistas
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...
PeerVoice•6 vistas
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...
Advancing Management of Limb-Girdle Muscular Dystrophy: Why a Genetic Diagnos...
PeerVoice•6 vistas
Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical ConsiderationsOncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
PeerVoice•5 vistas
Updates on HER3-Targeted Therapies in NSCLC and Breast CancerUpdates on HER3-Targeted Therapies in NSCLC and Breast Cancer
Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer
PeerVoice•11 vistas
Dual Duty: Protecting Cardiovascular Health in Patients With NarcolepsyDual Duty: Protecting Cardiovascular Health in Patients With Narcolepsy
Dual Duty: Protecting Cardiovascular Health in Patients With Narcolepsy
PeerVoice•6 vistas
After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SC...After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SC...
After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SC...
PeerVoice•7 vistas
Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment PlansClinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
PeerVoice•9 vistas
Mastering MET and cMET and Recognizing Their Role in Advanced NSCLCMastering MET and cMET and Recognizing Their Role in Advanced NSCLC
Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC
PeerVoice•6 vistas
Identifying Intervention Points in CKD and HF From Multidisciplinary ViewpointsIdentifying Intervention Points in CKD and HF From Multidisciplinary Viewpoints
Identifying Intervention Points in CKD and HF From Multidisciplinary Viewpoints
PeerVoice•5 vistas
Androgen Risk Reduction in Hereditary Angioedema: Why and How to Switch to Ta...Androgen Risk Reduction in Hereditary Angioedema: Why and How to Switch to Ta...
Androgen Risk Reduction in Hereditary Angioedema: Why and How to Switch to Ta...
PeerVoice•24 vistas
Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds an...Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds an...
Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds an...
PeerVoice•18 vistas
Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeti...Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeti...
Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeti...
PeerVoice•8 vistas
Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates...Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates...
Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates...
PeerVoice•10 vistas
Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ CancersHere’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
PeerVoice•13 vistas
Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease a...Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease a...
Handling Hyperkalaemia Without Compromising Care for Chronic Kidney Disease a...
PeerVoice•7 vistas
The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New ...The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New ...
The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New ...
PeerVoice•9 vistas
HER3-Targeted Therapies: How Might These Benefit Our Patients?HER3-Targeted Therapies: How Might These Benefit Our Patients?
HER3-Targeted Therapies: How Might These Benefit Our Patients?
PeerVoice•15 vistas

Último

perio-endo.pptxperio-endo.pptx
perio-endo.pptxDr. AISHWARYA PANDEY18 vistas•34 diapositivas
Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...
Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...PVI, PeerView Institute for Medical Education22 vistas•48 diapositivas
HEMODYNAMICS & NATURAL HISTORY OF PS.pptxHEMODYNAMICS & NATURAL HISTORY OF PS.pptx
HEMODYNAMICS & NATURAL HISTORY OF PS.pptxAparanji Gopidi10 vistas•64 diapositivas
endocrine system.pptxendocrine system.pptx
endocrine system.pptxmokshadatalele80 vistas•29 diapositivas
MCU.pptxMCU.pptx
MCU.pptxDr. Dheeraj Kumar 170 vistas•45 diapositivas
Principles Of Total Hip ReplacementPrinciples Of Total Hip Replacement
Principles Of Total Hip Replacementyasinawil211 vistas•82 diapositivas

Último(20)

perio-endo.pptxperio-endo.pptx
perio-endo.pptx
Dr. AISHWARYA PANDEY•18 vistas
Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...
Expert Insights on Optimizing Patient Outcomes With Novel EHL FVIII Strategie...
PVI, PeerView Institute for Medical Education•22 vistas
HEMODYNAMICS & NATURAL HISTORY OF PS.pptxHEMODYNAMICS & NATURAL HISTORY OF PS.pptx
HEMODYNAMICS & NATURAL HISTORY OF PS.pptx
Aparanji Gopidi•10 vistas
endocrine system.pptxendocrine system.pptx
endocrine system.pptx
mokshadatalele•80 vistas
MCU.pptxMCU.pptx
MCU.pptx
Dr. Dheeraj Kumar •170 vistas
Principles Of Total Hip ReplacementPrinciples Of Total Hip Replacement
Principles Of Total Hip Replacement
yasinawil2•11 vistas
LD50 and ED50.pptxLD50 and ED50.pptx
LD50 and ED50.pptx
KarabiAdak•9 vistas
GAMMA KNIFE.pdfGAMMA KNIFE.pdf
GAMMA KNIFE.pdf
Krishan Murari•16 vistas
Emerging trends of Nanotechnology and also other several technique in Pharmac...Emerging trends of Nanotechnology and also other several technique in Pharmac...
Emerging trends of Nanotechnology and also other several technique in Pharmac...
Anilmeher6•34 vistas
Skin,.pptxSkin,.pptx
Skin,.pptx
Munmun Kulsum•48 vistas
IVTh sem anticholinergics-converted unit-3.pptxIVTh sem anticholinergics-converted unit-3.pptx
IVTh sem anticholinergics-converted unit-3.pptx
UnitedGroupofInstitu1•11 vistas
BONE LOSS AND PATTERNS OF BONE DESTRUCTION.pptxBONE LOSS AND PATTERNS OF BONE DESTRUCTION.pptx
BONE LOSS AND PATTERNS OF BONE DESTRUCTION.pptx
Dr. AISHWARYA PANDEY•15 vistas
General Anaesthetic.pptxGeneral Anaesthetic.pptx
General Anaesthetic.pptx
Swatiingle7•12 vistas
Radiographic Exposure.pptxRadiographic Exposure.pptx
Radiographic Exposure.pptx
Dr. Dheeraj Kumar •37 vistas
Necrosis (Basics).pptxNecrosis (Basics).pptx
Necrosis (Basics).pptx
Superior University•44 vistas
AAO-NHS-Ethical-Rules-for-Otolaryngologists-1996AAO-NHS-Ethical-Rules-for-Otolaryngologists-1996
AAO-NHS-Ethical-Rules-for-Otolaryngologists-1996
MikeAdams260602•56 vistas
Pharma PCD Franchise Company in KarnatakaPharma PCD Franchise Company in Karnataka
Pharma PCD Franchise Company in Karnataka
Frisco Hill Pharmacia•34 vistas
Introduction to Medical Microbiology pdf file.pdfIntroduction to Medical Microbiology pdf file.pdf
Introduction to Medical Microbiology pdf file.pdf
Society for Microbiology and Infection care •23 vistas
PTC.pptxPTC.pptx
PTC.pptx
Dr. Dheeraj Kumar •89 vistas
NR511_Assignment_Presentation-v3 (Nov2021).pptxNR511_Assignment_Presentation-v3 (Nov2021).pptx
NR511_Assignment_Presentation-v3 (Nov2021).pptx
SumWan5•11 vistas